| | Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting to Be Held Virtually, Via Live Webcast at www.virtualshareholdermeeting.com/ | | |
| | The proxy statement and the | | |
| | You are cordially invited to attend the virtual Annual Meeting. Whether or not you expect to attend the Annual Meeting, PLEASE VOTE YOUR SHARES. As an alternative to voting online at the Annual Meeting, you may vote via the internet, by telephone or, if you receive a paper proxy card, by mailing the completed proxy card. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card. | | |
| | Even if you have voted by proxy, you may still vote online if you attend the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must follow the instructions from such organization and will need to obtain a proxy issued in your name from that record holder. | | |
| | | Page | | |||
| | | | 1 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 22 | | | |
| | | | 23 | | | |
| | | | 23 | | | |
| | | | 23 | | | |
| | | | 24 | | | |
| | | | | | ||
| | | | | | ||
| | | | 29 | |||
| | ||||||
| | | | | | ||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | 38 | | | ||
Transactions With Related Persons | | | | | 40 | | | |
| | | | | | |||
| | | | 40 | | |
| | | Page | | ||||
| | | | 40 | | | ||
| | | | 41 | | | ||
| | | | 42 | | | ||
| | | | | | |||
| | | | | | |||
Householding Of Proxy Materials | | | | | 55 | | | |
| | | | 55 | | | ||
| | | | | | |||
| | | | |||||
| |
| | Internet proxy voting is provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. | | |
| | | 1 | | | 2 | | | 3 | | | 4 | | | 5 | | |||||||||||||||
Gender(1) | | | | | M | | | | | | M | | | | | | M | | | | | | F | | | | | | M | | |
African American or Black | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Alaskan Native or American Indian | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Asian | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Hispanic or LatinX | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Native Hawaiian or Pacific Islander | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
White | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Two or more races or ethnicities | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LGBTQ+ | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Did not disclose demographic background | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 3 | | | | | | 3 | | | | | | | | |
Part II: Demographics Background | | | | | | | | | | | | | | | | | | | |
African American or Black | | | | | | | | | | | | | | | | | | | |
Alaskan Native or Native American | | | | | | | | | | | | | | | | | | | |
Asian | | | | | | | | | | | | | | | | | | | |
Hispanic or Latino | | | | | | | | | | | | | | | | | | | |
Native Hawaiian or Pacific Islander | | | | | | | | | | | | | | | | | | | |
White | | | | | 2 | | | | | | 3 | | | | | | | | |
Two or More Races or Ethnicities | | | | | | | | | | | | | | | | | | | |
LGBTQ+ | | | | | | | | | | | | | | | | | | | |
Did Not Disclose Demographic Background | | | | | 1 | | | | | | | | | | | | | | |
Name | | Audit | | Compensation | | Nominating and Corporate Governance | | | Audit | | Compensation | | Nominating and Corporate Governance | | ||||||||||||||||||||||||
Harrison M. Bains, Jr. | | | | X* | | | | | | | | | | X | | | | | | | ||||||||||||||||||
Jeffrey L. Ives, Ph.D. | | | | X | | | | | X | | | | | X | | | | | | X | | | | | X | | | | | X | | | ||||||
Martin Vogelbaum | | | | X | | | | | X* | | | | | X* | | | | | | X | | | | | X* | | | | | X* | | | ||||||
Susan Shiff, Ph.D. | | | | | | | | | X | | | | | X | | | | | | | | | | | X | | | | | X | | | ||||||
Total meetings during 2021 | | | | 4 | | | | | 3 | | | | | 0 | | | ||||||||||||||||||||||
Lisa von Moltke, M.D. | | | | | | | | | | | | | | X | | | ||||||||||||||||||||||
Helen M. Boudreau(2) | | | | X* | | | | | | | | | | | | | ||||||||||||||||||||||
Total meetings during 2023 | | | | 4 | | | | | 1 | | | | | 1 | | |
Name | | | Age | | | Position(s) | |
Christopher Posner | | | | | President, Chief Executive Officer and Director | | |
| | | | Chief | |||
| |||||||
Scott M. Terrillion | | | | | General Counsel, Secretary and Chief Compliance | ||
|
Name | | | Age | | | Position | |
Martin Vogelbaum | | | |||||
| | Director | | ||||
Jeffrey L. Ives, Ph.D. | | | | | Director | | |
Susan Shiff, Ph.D. | | | | | Director | | |
Lisa von Moltke, M.D. | | | 65 | | | Director | |
Helen M. Boudreau | | | 58 | | | Director | |
Director | | Fees Earned or Paid in Cash(1) | | Stock Awards(2)(4) | | Option Awards(3)(4) | | Total | | | Fees Earned or Paid in Cash(3) ($) | | Stock Awards(4)(5) ($) | | Option Awards(4)(5) ($) | | Total ($) | | ||||||||||||||||||||||||||||||||
Harrison M. Bains, Jr.(1) | | | | 60,772 | | | | | 99,999 | | | | | 99,993 | | | | | 260,764 | | | |||||||||||||||||||||||||||||
Martin Vogelbaum | | | $ | 110,000 | | | | $ | 188,064 | | | | $ | 201,308 | | | | $ | 499,372 | | | | | | 120,000 | | | | | 199,997 | | | | | 199,989 | | | | | 519,986 | | | ||||||||
Harrison M. Bains, Jr. | | | | 60,000 | | | | | 94,032 | | | | | 100,654 | | | | | 254,686 | | | |||||||||||||||||||||||||||||
Jeffrey L. Ives, Ph.D. | | | | 54,250 | | | | | 94,032 | | | | | 100,654 | | | | | 248,936 | | | | | | 72,500 | | | | | 99,999 | | | | | 99,993 | | | | | 272,492 | | | ||||||||
Christopher Posner(5) | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Susan Shiff, Ph.D. | | | | 52,500 | | | | | 94,032 | | | | | 100,654 | | | | | 247,186 | | | | | | 62,500 | | | | | 99,999 | | | | | 99,993 | | | | | 262,492 | | | ||||||||
Lisa von Moltke, M.D. | | | | 55,000 | | | | | 99,999 | | | | | 99,993 | | | | | 254,992 | | | |||||||||||||||||||||||||||||
Helen M. Boudreau(2) | | | | 26,043 | | | | | — | | | | | 349,964 | | | | | 376,007 | | |
Director | | | RSUs | | | Number of Shares Underlying Options | | ||||||
Martin Vogelbaum | | | | | 135,152 | | | | | | 257,616 | | |
Jeffrey L. Ives, Ph.D. | | | | | 64,638 | | | | | | 100,596 | | |
Susan Shiff, Ph.D. | | | | | 51,438 | | | | | | 110,757 | | |
Lisa von Moltke, M.D. | | | | | 32,362 | | | | | | 90,802 | | |
Helen M. Boudreau | | | | | — | | | | | | 155,747 | | |
| | | Member Annual Service Retainer | | | Chairperson / Lead Independent Director and Committee Chair Annual Service Retainer | | ||||||
Board of Directors | | | | $ | 40,000 | | | | | $ | 75,000 | | |
Audit Committee | | | | | 10,000 | | | | | | 20,000 | | |
Compensation Committee | | | | | 7,500 | | | | | | 15,000 | | |
Nominating and Corporate Governance Committee | | | | | 5,000 | | | | | | 10,000 | | |
| | | Member Annual Service Retainer | | | Chairperson / Lead Independent Director and Committee Chair Annual Service Retainer | | ||||||
Board of Directors | | | | $ | 50,000 | | | | | $ | 35,000 | | |
Audit Committee | | | | | 10,000 | | | | | | 20,000 | | |
Compensation Committee | | | | | 7,500 | | | | | | 15,000 | | |
Nominating and Corporate Governance Committee | | | | | 5,000 | | | | | | 10,000 | | |
| What we do: | | | What we do not do: | |
| ✓ Performance metrics tied to ✓ Multi-year vesting requirements. The equity awards we grant to our executive officers generally vest over multi-year periods, consistent with current market practice and our retention objectives. ✓ Double-trigger termination rights. Our agreements with our executive officers require both a change-in-control and a termination of employment for full severance benefits to be triggered. ✓ Independent compensation committee. Our compensation committee is comprised solely of independent members of our Board. ✓ Independent compensation consultant. Our compensation committee uses an independent compensation consultant that provides no other material services to the | | | ✘ No ✘ No special perquisites. Except as otherwise discussed below, we generally do not provide our executives with perquisites or other personal benefits that differ materially from those available to employees generally. ✘ No retirement plans other than 401(k) ✘ No special health or welfare benefits. We do not provide our executives with any special health or welfare benefits. Our executive officers participate in the same broad-based ✘ Hedging, short selling and pledging prohibited. Our insider trading policy prohibits our executive officers and directors from hedging, short selling or pledging our securities. | |
Name and Principal Position | | | Year | | | Salary | | | Bonus | | | Stock Awards(1) | | | Option Awards(2) | | | Non-Equity Incentive Plan Compensation(3) | | | All Other Compensation(4) | | | Total | | ||||||||||||||||||||||||
Christopher Posner President and Chief Executive Officer | | | | | 2023 | | | | | $ | 728,000 | | | | | | — | | | | | $ | 0 | | | | | $ | 1,769,000 | | | | | $ | 414,960 | | | | | $ | 10,509 | | | | | $ | 2,922,469 | | |
| | | 2022 | | | | | | 700,000 | | | | | $ | 200,000 | | | | | | 407,940 | | | | | | 898,280 | | | | | | 294,000 | | | | | | 9,759 | | | | | | 2,509,979 | | | ||
Ryan Maynard Chief Financial Officer | | | | | 2023 | | | | | $ | 478,400 | | | | | | — | | | | | $ | 0 | | | | | $ | 573,156 | | | | | $ | 181,792 | | | | | $ | 10,509 | | | | | $ | 1,243,857 | | |
| | | 2022 | | | | | | 140,600 | | | | | $ | 8,312 | | | | | | — | | | | | | 1,701,405 | | | | | | 38,788 | | | | | | 197 | | | | | | 1,889,302 | | | ||
Joana Goncalves, M.D. former Chief Medical Officer | | | | | 2023 | | | | | $ | 500,240 | | | | | | — | | | | | $ | 0 | | | | | $ | 573,156 | | | | | $ | 190,091 | | | | | $ | 10,509 | | | | | $ | 1,273,996 | | |
| | | 2022 | | | | | | 481,000 | | | | | $ | 121,860 | | | | | | 209,200 | | | | | | 593,904 | | | | | | 134,680 | | | | | | 9,711 | | | | | | 1,550,355 | | |
Executive | | | 2021 Base Salary | | | Percentage Increase in Base Salary from 2020(1) | | ||||||
Christopher Posner | | | | $ | 680,000 | | | | | | —(2) | | |
Derek Chalmers, Ph.D., D.Sc. | | | | | 594,000 | | | | | | 3% | | |
Frédérique Menzaghi, Ph.D. | | | | | 465,000 | | | | | | 3 | | |
Joana Goncalves, M.D. | | | | | 465,000 | | | | | | 3 | | |
Scott Terrillion | | | | | 424,000 | | | | | | 3 | | |
Thomas Reilly | | | | | 412,000 | | | | | | 3 | | |
| | | Target Bonus as Percentage of Base Salary | | | Target Bonus | | ||||||
Frédérique Menzaghi, Ph.D. | | | | | 40% | | | | | $ | 186,000 | | |
Joana Goncalves, M.D. | | | | | 40 | | | | | | 186,000 | | |
Scott Terrillion | | | | | 40 | | | | | | 169,600 | | |
Thomas Reilly | | | | | 40 | | | | | | 164,800 | | |
Named Executive Officer | | | Target Bonus % | | |||
Christopher Posner | | | | | 60 | | |
Ryan Maynard | | | | | 40 | | |
Joana Goncalves, M.D. | | | | | 40 | | |
Named Executive Officer | | | 2021 Annual Bonus Payment | | | Percent of Target Bonus | | ||||||
Frédérique Menzaghi, Ph.D. | | | | $ | 167,400 | | | | | | 90% | | |
Joana Goncalves, M.D. | | | | | 167,400 | | | | | | 90 | | |
Scott Terrillion | | | | | 169,600 | | | | | | 100 | | |
Thomas Reilly | | | | | 164,800 | | | | | | 100 | | |
Executive | | | Stock Option Grant (# shares) | | |||
| | | | | | ||
| | | | | | ||
Joana Goncalves, M.D. | | | | | |||
| |
| | | Performance-based RSUs (# shares) | | |||||||||
Executive | | | Target | | | Stretch | | ||||||
| | | | | | | | | | | |||
| | | | | | | | | | | |||
Joana Goncalves, M.D. | | | | | | | | | | ||||
| |
Name and Principal Position | | | Year | | | Salary | | | Bonus | | | Stock Awards(1) | | | Option Awards(2) | | | Non-Equity Incentive Plan Compensation(3) | | | All Other Compensation(4) | | | Total | | ||||||||||||||||||||||||
Christopher Posner (5) President and Chief Executive Officer | | | | | 2021 | | | | | $ | 116,167(10) | | | | | $ | 268,000(6) | | | | | $ | 2,583,896 | | | | | $ | 6,885,579 | | | | | | — | | | | | $ | 47,734(7) | | | | | $ | 9,901,376 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
Derek Chalmers, Ph.D., D.Sc. Former President and Chief Executive Officer | | | | | 2021 | | | | | | 570,062 | | | | | | — | | | | | | 1,665,680 | | | | | | 7,950,174 | | | | | | — | | | | | | 10,869 | | | | | | 10,196,785 | | |
| | | 2020 | | | | | | 576,800 | | | | | | 86,520(8) | | | | | | 818,000 | | | | | | 1,075,130 | | | | | | 346,080 | | | | | | 11,079 | | | | | | 2,913,609 | | | ||
| | | 2019 | | | | | | 560,000 | | | | | | — | | | | | | — | | | | | | 2,551,783 | | | | | | 310,800 | | | | | | 11,034 | | | | | | 3,433,617 | | | ||
| | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||
Thomas Reilly(5) Chief Financial Officer | | | | | 2021 | | | | | | 412,000 | | | | | | 82,400(9) | | | | | | 139,067 | | | | | | — | | | | | | 164,800 | | | | | | 11,736 | | | | | | 810,003 | | |
| | | 2020 | | | | | | 100,000(10) | | | | | | 70,000(11) | | | | | | — | | | | | | 1,417,868 | | | | | | — | | | | | | 590 | | | | | | 1,588,458 | | | ||
| | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Frédérique Menzaghi, Ph.D. Chief Scientific Officer and Senior | | | | | 2021 | | | | | | 465,000 | | | | | | 93,000(9) | | | | | | 486,397 | | | | | | 423,776 | | | | | | 257,709 | | | | | | 11,229 | | | | | | 1,737,111 | | |
| | | 2020 | | | | | | 451,200 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 323,349 | | | | | | 10,959 | | | | | | 1,391,310 | | | ||
| | | 2019 | | | | | | 438,000 | | | | | | — | | | | | | — | | | | | | 1,628,797 | | | | | | 148,920 | | | | | | 10,914 | | | | | | 2,226,631 | | | ||
| | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Joana Goncalves, M.D.(5) Chief Medical Officer | | | | | 2021 | | | | | | 465,000 | | | | | | 93,000(9) | | | | | | 486,397 | | | | | | 423,776 | | | | | | 257,709 | | | | | | 11,061 | | | | | | 1,736,943 | | |
| | | 2020 | | | | | | 451,200 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 270,789 | | | | | | 10,911 | | | | | | 1,338,702 | | | ||
| | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Scott Terrillion General Counsel, Secretary and Chief Compliance Officer | | | | | 2021 | | | | | | 424,000 | | | | | | 84,800(9) | | | | | | 472,553 | | | | | | 423,776 | | | | | | 169,600 | | | | | | 11,229 | | | | | | 1,585,958 | | |
| | | 2020 | | | | | | 412,000 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 164,800 | | | | | | 11,079 | | | | | | 1,193,681 | | | ||
| | | 2019 | | | | | | 400,000 | | | | | | — | | | | | | — | | | | | | 814,399 | | | | | | 160,000 | | | | | | 11,034 | | | | | | 1,385,433 | | |
| | | | | | | | | Estimated Future Payouts under Non-Equity Incentive Plan Awards(1) | | | Estimated Future Payouts under Equity Incentive Plan Awards(2) | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | | All Other Option Awards: Number of Securities Underlying Options(#) | | | Exercise or Base Price of Option Awards ($/Share) | | | Grant Date Fair Value of Stock and Option Awards($)(3) | | ||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Threshold ($) | | | Target (#) | | | Maximum (#) | | | Threshold ($) | | | Target (#) | | | Maximum (#) | | |||||||||||||||||||||||||||||||||||||||||||||
Christopher Posner | | | | | 6/3/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 7,200(4) | | | | | | | | | | | | | | | | | | 94,032 | | |
| | | 6/3/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,800(4) | | | | | | 13.06 | | | | | | 100,654 | | | ||
| | | 10/29/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 566,000 | | | | | | 16.83 | | | | | | 6,784,925 | | | ||
| | | 10/29/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,941(5) | | | | | | | | | | | | | | | | | | 100,004 | | | ||
| | | 10/29/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 142,000(6) | | | | | | | | | | | | | | | | | | 2,389,860 | | | ||
Derek Chalmers, Ph.D.., D. Sc. | | | | | 3/30/2021 | | | | | | — | | | | | | 356,400 | | | | | | — | | | | | | 17,333 | | | | | | 52,000 | | | | | | 62,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 52,000(7) | | | | | | | | | | | | | | | | | | 1,070,680 | | | ||
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 103,000 | | | | | | 20.59 | | | | | | 1,364,029 | | | ||
| | | 11/1/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 33,333 | | | | | | | | | | | | | | | | | | 595,000(10) | | | ||
| | | 11/1/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,224,007 | | | | | | | | | | | | 6,586,145(11) | | | ||
Thomas Reilly | | | | | 3/30/2021 | | | | | | — | | | | | | 164,800 | | | | | | — | | | | | | 5,333 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 12/17/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,170(8) | | | | | | | | | | | | | | | | | | 139,067 | | | ||
Frédérique Menzaghi, Ph.D. | | | | | 3/30/2021 | | | | | | — | | | | | | 186,000 | | | | | | — | | | | | | 6,400 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000(9) | | | | | | | | | | | | | | | | | | 329,440 | | | ||
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 20.59 | | | | | | 423,776 | | | ||
| | | 12/17/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 12,607(8) | | | | | | | | | | | | | | | | | | 156,957 | | | ||
Joana Goncalves, M.D. | | | | | 3/30/2021 | | | | | | — | | | | | | 186,000 | | | | | | — | | | | | | 6,400 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000(9) | | | | | | | | | | | | | | | | | | 329,440 | | | ||
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 20.59 | | | | | | 423,776 | | | ||
| | | 12/17/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 12,607(8) | | | | | | | | | | | | | | | | | | 156,957 | | | ||
Scott Terrillion | | | | | 3/30/2021 | | | | | | — | | | | | | 169,600 | | | | | | — | | | | | | 5,333 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000(9) | | | | | | | | | | | | | | | | | | 329,440 | | | ||
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 20.59 | | | | | | 423,776 | | | ||
| | | 12/17/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,495(8) | | | | | | | | | | | | | | | | | | 143,113 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Option (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares of Units of Stock That Have Not Vested($)(2) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested(#)(3) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested($)(2) | | |||||||||||||||||||||||||||
Christopher Posner President and Chief Executive Officer | | | | | 8/2/2018 | | | | | | 35,000 | | | | | | — | | | | | | 17.94 | | | | | | 8/2/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/4/2019 | | | | | | 9,000 | | | | | | — | | | | | | 20.47 | | | | | | 6/4/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/4/2020 | | | | | | 10,800 | | | | | | — | | | | | | 15.62 | | | | | | 6/4/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/3/2021 | | | | | | — | | | | | | 10,800(4) | | | | | | 13.06 | | | | | | 6/3/2031 | | | | | | 7,200(5) | | | | | | 87,696 | | | | | | — | | | | | | — | | | ||
| | | 10/29/2021 | | | | | | — | | | | | | 566,000(6) | | | | | | 16.83 | | | | | | 10/29/2031 | | | | | | 147,942(7) | | | | | | 1,801,934 | | | | | | — | | | | | | — | | | ||
Derek Chalmers, Ph.D., D.Sc. Former President and Chief Executive Officer | | | | | 1/30/2014 | | | | | | 80,000 | | | | | | — | | | | | | 11.00 | | | | | | 1/30/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/15/2015 | | | | | | 165,000 | | | | | | — | | | | | | 10.82 | | | | | | 6/15/2025 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/30/2016 | | | | | | 191,000 | | | | | | — | | | | | | 6.00 | | | | | | 3/30/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/8/2017 | | | | | | 225,000 | | | | | | — | | | | | | 17.41 | | | | | | 3/8/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/9/2018 | | | | | | 175,781 | | | | | | 11,719(8) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 161,562 | | | | | | 73,438(8) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 45,833 | | | | | | 54,167(8) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 33,333(8) | | | | | | 405,996 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 19,312 | | | | | | 83,688(8) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 52,000(8) | | | | | | 633,360 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 44,666(8) | | | | | | 544,032 | | | ||
Thomas Reilly Chief Financial Officer | | | | | 10/01/2020 | | | | | | 51,041 | | | | | | 123,959(9) | | | | | | 12.74 | | | | | | 10/1/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,666 | | | | | | 251,712 | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,170(10) | | | | | | 136,051 | | | | | | — | | | | | | — | | | ||
Frédérique Menzaghi, Ph.D. Chief Scientific Officer and Senior Vice President, Research and Development | | | | | 1/30/2014 | | | | | | 40,000 | | | | | | — | | | | | | 11.00 | | | | | | 1/30/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/15/2015 | | | | | | 60,000 | | | | | | — | | | | | | 10.82 | | | | | | 6/15/2025 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/30/2016 | | | | | | 65,000 | | | | | | — | | | | | | 6.00 | | | | | | 3/30/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/8/2017 | | | | | | 75,000 | | | | | | — | | | | | | 17.41 | | | | | | 3/8/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/9/2018 | | | | | | 54,140 | | | | | | 3,610(11) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 103,125 | | | | | | 46,875(11) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 14,666 | | | | | | 17,334(11) | | | | | | 16.36 | | | | | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,666(12) | | | | | | 129,912 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 6,000 | | | | | | 26,000(11) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 16,000(12) | | | | | | 194,880 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 16,400 | | | | | | 199,752 | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 12,607(10) | | | | | | 153,553 | | | | | | — | | | | | | — | | | ||
Joana Goncalves, M.D. Chief Medical Officer | | | | | 10/22/2018 | | | | | | 197,916 | | | | | | 52,084(9) | | | | | | 19.27 | | | | | | 10/22/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/24/2020 | | | | | | 14,666 | | | | | | 17,334(11) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,666(12) | | | | | | 129,912 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 6,000 | | | | | | 26,000(11) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 16,000(12) | | | | | | 194,880 | | | | | | 19,600 | | | | | | 238,728 | | | ||
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 12,607(10) | | | | | | 153,553 | | | | | | — | | | | | | — | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Option (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares of Units of Stock That Have Not Vested($)(2) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested(#)(3) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested($)(2) | | |||||||||||||||||||||||||||
Scott M. Terrillion General Counsel, Secretary and Chief Compliance Officer | | | | | 11/28/2016 | | | | | | 135,000 | | | | | | — | | | | | | 9.22 | | | | | | 11/28/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/9/2018 | | | | | | 43,593 | | | | | | 2,907(11) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 51,562 | | | | | | 23,438(11) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 14,666 | | | | | | 17,334(11) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,666(12) | | | | | | 129,912 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 6,000 | | | | | | 26,000(11) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 16,000(12) | | | | | | 194,880 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,666 | | | | | | 251,712 | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,495(10) | | | | | | 140,009 | | | | | | — | | | | | | — | | |
| | | Stock Awards | | |||||||||
Name | | | Number of Shares Acquired on Vesting | | | Value Realized on Vesting | | ||||||
| | | (#) | | | ($) | | ||||||
Christopher Posner | | | | | — | | | | | | — | | |
Derek Chalmers, Ph.D., D.Sc. | | | | | 62,751 | | | | | | 1,138,257 | | |
Thomas Reilly | | | | | 5,334 | | | | | | 79,370 | | |
Frédérique Menzaghi, Ph.D. | | | | | 32,934 | | | | | | 586,888 | | |
Joana Goncalves, M.D. | | | | | 25,734 | | | | | | 460,512 | | |
Scott M. Terrillion | | | | | 26,668 | | | | | | 484,030 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Option (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares of Units of Stock That Have Not Vested ($)(2) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)(3) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(2) | | |||||||||||||||||||||||||||
Christopher Posner President and Chief Executive Officer | | | | | 8/2/2018 | | | | | | 35,000 | | | | | | — | | | | | | 17.94 | | | | | | 08/02/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/4/2019 | | | | | | 9,000 | | | | | | — | | | | | | 20.47 | | | | | | 06/04/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/4/2020 | | | | | | 10,800 | | | | | | — | | | | | | 15.62 | | | | | | 06/04/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/3/2021 | | | | | | 10,800 | | | | | | — | | | | | | 13.06 | | | | | | 06/03/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 10/29/2021 | | | | | | 283,000 | | | | | | 283,000(4) | | | | | | 16.83 | | | | | | 10/29/2031 | | | | | | 71,000(5) | | | | | | 52,753 | | | | | | — | | | | | | — | | | ||
| | | 2/25/2022 | | | | | | 55,458 | | | | | | 65,542(6) | | | | | | 10.46 | | | | | | 2/25/2032 | | | | | | 26,000(7) | | | | | | 19,318 | | | | | | — | | | | | | — | | | ||
| | | 3/1/2023 | | | | | | 46,875 | | | | | | 203,125(6) | | | | | | 10.06 | | | | | | 3/1/2033 | | | | | | — | | | | | | — | | | | | | 181,000 | | | | | | 134,483 | | | ||
Ryan Maynard Chief Financial Officer | | | | | 9/12/2022 | | | | | | 70,132 | | | | | | 154,688(8) | | | | | | 10.75 | | | | | | 9/12/2032 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/1/2023 | | | | | | 15,187 | | | | | | 65,813(6) | | | | | | 10.06 | | | | | | 3/1/2033 | | | | | | — | | | | | | — | | | | | | 40,000 | | | | | | 29,720 | | | ||
Joana Goncalves, M.D. former Chief Medical Officer | | | | | 10/22/2018 | | | | | | 250,000 | | | | | | — | | | | | | 19.27 | | | | | | 10/22/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/24/2020 | | | | | | 30,666 | | | | | | 1,334(6) | | | | | | 16.36 | | | | | | 02/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 22,000 | | | | | | 10,000(6) | | | | | | 20.59 | | | | | | 03/30/2031 | | | | | | 5,334(7) | | | | | | 3,963 | | | | | | — | | | | | | — | | | ||
| | | 2/25/2022 | | | | | | 36,666 | | | | | | 43,334(6) | | | | | | 10.46 | | | | | | 2/25/2032 | | | | | | 13,334(7) | | | | | | 9,907 | | | | | | — | | | | | | — | | | ||
| | | 3/1/2023 | | | | | | 15,187 | | | | | | 65,813(6) | | | | | | 10.06 | | | | | | 3/1/2033 | | | | | | — | | | | | | — | | | | | | 40,000 | | | | | | 29,720 | | |
Name | | | Benefit | | | Termination without Cause | | | Resignation for Good Reason | | | CIC Termination | | |||||||||
Christopher Posner | | | Severance Payments | | | | $ | 680,000 | | | | | $ | 680,000 | | | | | $ | 1,020,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 47,319 | | | | | | 47,319 | | | | | | 71,979 | | | ||
| Target Bonus | | | | | 408,000 | | | | | | 408,000 | | | | | | 612,000 | | | ||
| Vesting Acceleration(1) | | | | | 592,460 | | | | | | 592,460 | | | | | | 1,889,630 | | | ||
| Benefit Total | | | | $ | 1,727,779 | | | | | $ | 1,727,779 | | | | | $ | 3,593,609 | | | ||
Frédérique Menzaghi, Ph.D. | | | Severance Payments | | | | $ | 348,750 | | | | | $ | 348,750 | | | | | $ | 465,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 1,648 | | | | | | 1,648 | | | | | | 2,198 | | | ||
| Target Bonus | | | | | 186,000 | | | | | | 186,000 | | | | | | 186,000 | | | ||
| Vesting Acceleration(1) | | | | | — | | | | | | — | | | | | | 478,345 | | | ||
| Benefit Total | | | | $ | 536,398 | | | | | $ | 536,398 | | | | | $ | 1,131,543 | | | ||
Joana Goncalves, M.D. | | | Severance Payments | | | | $ | 348,750 | | | | | $ | 348,750 | | | | | $ | 465,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 31,932 | | | | | | 31,932 | | | | | | 42,575 | | | ||
| Target Bonus | | | | | 186,000 | | | | | | 186,000 | | | | | | 186,000 | | | ||
| Vesting Acceleration(1) | | | | | — | | | | | | — | | | | | | 478,345 | | | ||
| Benefit Total | | | | $ | 566,682 | ��� | | | | $ | 566,682 | | | | | $ | 1,171,920 | | | ||
Thomas Reilly | | | Severance Payments | | | | $ | 309,000 | | | | | $ | 309,000 | | | | | $ | 412,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 31,838 | | | | | | 31,838 | | | | | | 42,450 | | | ||
| Target Bonus | | | | | 164,800 | | | | | | 164,800 | | | | | | 164,800 | | | ||
| Vesting Acceleration(1) | | | | | — | | | | | | — | | | | | | 136,051 | | | ||
| Benefit Total | | | | $ | 505,638 | | | | | $ | 505,638 | | | | | $ | 755,301 | | |
Name | | | Benefit | | | Termination without Cause | | | Resignation for Good Reason | | | CIC Termination | | |||||||||
Scott Terrillion | | | Severance Payments | | | | $ | 318,000 | | | | | $ | 318,000 | | | | | $ | 424,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 32,054 | | | | | | 32,054 | | | | | | 42,739 | | | ||
| Target Bonus | | | | | 169,600 | | | | | | 169,600 | | | | | | 169,600 | | | ||
| Vesting Acceleration(1) | | | | | — | | | | | | — | | | | | | 464,801 | | | ||
| Benefit Total | | | | $ | 519,654 | | | | | $ | 519,654 | | | | | $ | 1,101,140 | | |
Year | | | Summary Compensation Table Total for Christopher Posner(1) ($) | | | Summary Compensation Table Total for Derek Chalmers(1) ($) | | | Compensation Actually Paid to Christopher Posner(1)(2)(3) ($) | | | Compensation Actually Paid to Derek Chalmers(1)(2)(3) ($) | | | Average Summary Compensation Table Total for Non-PEO NEOs(1) ($) | | | Average Compensation Actually Paid to Non-PEO NEOs(1)(2)(3) ($) | | | Value of Initial Fixed $100 Investment based on TSR ($)(4) | | | Net Income ($ Millions) | | ||||||||||||||||||||||||
2023 | | | | | 4,743,329 | | | | | | — | | | | | | (2,735,603) | | | | | | — | | | | | | 1,661,327 | | | | | | (817,170) | | | | | | 4.91 | | | | | | (11.85) | | |
2022 | | | | | 2,509,979 | | | | | | — | | | | | | 1,365,402 | | | | | | — | | | | | | 1,719,829 | | | | | | 1,953,544 | | | | | | 70.98 | | | | | | (85.5) | | |
2021 | | | | | 9,901,376 | | | | | | 10,196,785 | | | | | | 6,770,961 | | | | | | 3,949,591 | | | | | | 1,467,504 | | | | | | 1,099,179 | | | | | | 80.50 | | | | | | (88.4) | | |
| | 2021 | | | | 2022 – 2023 | | |
| | Frédérique Menzaghi, Ph.D. | | | | Joana Goncalves, M.D. | | |
| | Joana Goncalves, M.D. | | | | Ryan Maynard | | |
| | Scott Terrillion | | | | | | |
| | Thomas Reilly | | | | | | |
Year | | | Summary Compensation Table Total for PEO 1 ($) | | | Exclusion of Stock Awards and Option Awards for PEO 1 ($) | | | Inclusion of Equity Values for PEO 1 ($) | | | Compensation Actually Paid to PEO 1 ($) | | ||||||||||||
2023 | | | | | 4,743,329 | | | | | | (3,589,860) | | | | | | (3,889,072) | | | | | | (2,735,603) | | |
Year | | | Average Summary Compensation Table Total for Non-PEO NEOs ($) | | | Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs ($) | | | Average Inclusion of Equity Values for Non-PEO NEOs ($) | | | Average Compensation Actually Paid to Non-PEO NEOs ($) | | ||||||||||||
2023 | | | | | 1,661,327 | | | | | | (975,556) | | | | | | (1,502,941) | | | | | | (817,170) | | |
Year | | | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for PEO 1 ($) | | | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for PEO 1 ($) | | | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for PEO 1 ($) | | | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for PEO 1 ($) | | | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for PEO 1 ($) | | | Total – Inclusion of Equity Values for PEO 1 ($) | | ||||||||||||||||||
2023 | | | | | 157,175 | | | | | | (3,218,622) | | | | | | 74,225 | | | | | | (901,850) | | | | | | — | | | | | | (3,889,072) | | |
Year | | | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($) | | | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs ($) | | | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($) | | | Total – Average Inclusion of Equity Values for Non-PEO NEOs ($) | | ||||||||||||||||||
2023 | | | | | 40,895 | | | | | | (1,076,410) | | | | | | 24,047 | | | | | | (491,473) | | | | | | — | | | | | | (1,502,941) | | |
Plan Category | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted- average exercise price of outstanding options, warrants and rights (b)(2) | | Number of securities remaining available for future issuance under equity compensation plans (excluding shares of common stock reflected in column (a))(c) | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted- average exercise price of outstanding options, warrants and rights (b)(2) | | Number of securities remaining available for future issuance under equity compensation plans (excluding shares of common stock reflected in column (a))(c)(4) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders(1) | | | | 6,464,780 | | | | $ | 15.50 | | | | | 70,157(3) | | | | | | 8,463,971(3) | | | | | 12.12 | | | | | 1,252,843 | | | ||||||
Equity compensation plans not approved by security holders (4) | | | | 47,500 | | | | $ | 25.88 | | | | | 252,500 | | | ||||||||||||||||||||||
Equity compensation plans not approved by security holders | | | | — | | | | | — | | | | | 300,000(5) | | | ||||||||||||||||||||||
Total | | | | 6,512,280 | | | | $ | 15.58 | | | | | 322,657 | | | | | | 8,463,971 | | | | | 12.12 | | | | | 1,552,843 | | |
| | Year ended December 31, | | | Year ended December 31, | | ||||||||||||||||||||
| | 2021 | | 2020 | | | 2023 | | 2022 | | ||||||||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||||||||
Audit fees(a) | | | $ | 732 | | | | $ | 616 | | | |||||||||||||||
Tax fees(b) | | | | 15 | | | | | — | | | |||||||||||||||
Audit Fees(1) | | | $ | 1,039 | | | | $ | 870 | | | |||||||||||||||
Total | | | $ | 747 | | | | $ | 616 | | | | | $ | 1,039 | | | | $ | 870 | | |
Name of beneficial owner | | | Number of Shares Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
5% stockholders: | | | | | | | | | | | | | |
Vifor (International) Ltd.(1) | | | | | 7,396,770 | | | | | | 13.8% | | |
Blackrock, Inc.(2) | | | | | 7,199,126 | | | | | | 13.4 | | |
The Vanguard Group(3) | | | | | 3,032,762 | | | | | | 5.7 | | |
Directors and named executive officers: | | | | | | | | | | | | | |
Christopher Posner(4) | | | | | 93,193 | | | | | | * | | |
Thomas Reilly(5) | | | | | 82,057 | | | | | | * | | |
Frédérique Menzaghi, Ph.D.(6) | | | | | 567,508 | | | | | | 1.1 | | |
Scott M. Terrillion(7) | | | | | 325,558 | | | | | | * | | |
Joana Goncalves, M.D.(8) | | | | | 282,578 | | | | | | * | | |
Martin Vogelbaum(9) | | | | | 153,860 | | | | | | * | | |
Harrison M. Bains, Jr.(10) | | | | | 132,500 | | | | | | * | | |
Jeffrey L. Ives, Ph.D.(11) | | | | | 90,800 | | | | | | * | | |
Susan Shiff, Ph.D.(12) | | | | | 40,166 | | | | | | * | | |
Derek Chalmers, Ph.D., D.Sc.(13) | | | | | 2,060,905 | | | | | | 3.8 | | |
All current executive officers and directors as a group (9 persons)(14) | | | | | 1,768,220 | | | | | | 3.2% | | |
Name of beneficial owner | | | Number of Shares Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
5% stockholders: | | | | | | | | | | | | | |
Vifor (International) Ltd(1) | | | | | 7,396,770 | | | | | | 13.5% | | |
Blackrock, Inc.(2) | | | | | 3,554,258 | | | | | | 6.5% | | |
Directors and named executive officers: | | | | | | | | | | | | | |
Christopher Posner(3) | | | | | 674,599 | | | | | | 1.2% | | |
Ryan Maynard(4) | | | | | 125,387 | | | | | | * | | |
Joana Goncalves, M.D.(5) | | | | | 419,055 | | | | | | * | | |
Martin Vogelbaum(6) | | | | | 192,681 | | | | | | * | | |
Helen M. Boudreau(7) | | | | | 38,936 | | | | | | * | | |
Jeffrey L. Ives, Ph.D.(8) | | | | | 116,072 | | | | | | * | | |
Susan Shiff, Ph.D.(9) | | | | | 81,272 | | | | | | * | | |
Lisa von Moltke, M.D.(10) | | | | | 65,796 | | | | | | * | | |
All current executive officers and directors as a group (8 persons)(11) | | | | | 1,739,035 | | | | | | 3.1% | | |
Status | | | Number of Shares of Common Stock Authorized | | | Number of Shares of Common Stock Issued and Outstanding | | | Number of Shares of Common Stock Reserved for Future Issuance | | | Number of Shares of Common Stock Authorized but Unissued and Unreserved | | ||||||||||||
Pre-Reverse Stock Split | | | | | 200,000,000 | | | | | | 54,667,079 | | | | | | 11,464,860 | | | | | | 133,868,061 | | |
Post-Reverse Stock Split 1:4 | | | | | 50,000,000 | | | | | | 13,666,769 | | | | | | 2,866,215 | | | | | | 33,467,016 | | |
Post-Reverse Stock Split 1:5 | | | | | 40,000,000 | | | | | | 10,933,415 | | | | | | 2,292,972 | | | | | | 26,773,613 | | |
Post-Reverse Stock Split 1:6 | | | | | 33,333,333 | | | | | | 9,111,179 | | | | | | 1,910,810 | | | | | | 22,311,344 | | |
Post-Reverse Stock Split 1:7 | | | | | 28,571,429 | | | | | | 7,809,582 | | | | | | 1,637,837 | | | | | | 19,124,010 | | |
Post-Reverse Stock Split 1:8 | | | | | 25,000,000 | | | | | | 6,833,384 | | | | | | 1,433,107 | | | | | | 16,733,509 | | |
Post-Reverse Stock Split 1:9 | | | | | 22,222,222 | | | | | | 6,074,119 | | | | | | 1,273,873 | | | | | | 14,874,230 | | |
Post-Reverse Stock Split 1:10 | | | | | 20,000,000 | | | | | | 5,466,707 | | | | | | 1,146,486 | | | | | | 13,386,807 | | |
Post-Reverse Stock Split 1:11 | | | | | 18,181,818 | | | | | | 4,969,734 | | | | | | 1,042,260 | | | | | | 12,169,824 | | |
Post-Reverse Stock Split 1:12 | | | | | 16,666,667 | | | | | | 4,555,589 | | | | | | 955,405 | | | | | | 11,155,673 | | |
Status | | | Number of Shares of Common Stock Authorized | | | Number of Shares of Common Stock Issued and Outstanding | | | Number of Shares of Common Stock Reserved for Future Issuance | | | Number of Shares of Common Stock Authorized but Unissued and Unreserved | | ||||||||||||
Pre-Reverse Stock Split | | | | | 100,000,000 | | | | | | 54,667,079 | | | | | | 11,464,860 | | | | | | 33,868,061 | | |
Post-Reverse Stock Split 1:4 | | | | | 25,000,000 | | | | | | 13,666,769 | | | | | | 2,866,215 | | | | | | 8,467,016 | | |
Post-Reverse Stock Split 1:5 | | | | | 20,000,000 | | | | | | 10,933,415 | | | | | | 2,292,972 | | | | | | 6,773,613 | | |
Post-Reverse Stock Split 1:6 | | | | | 16,666,667 | | | | | | 9,111,179 | | | | | | 1,910,810 | | | | | | 5,644,678 | | |
Post-Reverse Stock Split 1:7 | | | | | 14,285,714 | | | | | | 7,809,582 | | | | | | 1,637,837 | | | | | | 4,838,295 | | |
Post-Reverse Stock Split 1:8 | | | | | 12,500,000 | | | | | | 6,833,384 | | | | | | 1,433,107 | | | | | | 4,233,509 | | |
Post-Reverse Stock Split 1:9 | | | | | 11,111,111 | | | | | | 6,074,119 | | | | | | 1,273,873 | | | | | | 3,763,119 | | |
Post-Reverse Stock Split 1:10 | | | | | 10,000,000 | | | | | | 5,466,707 | | | | | | 1,146,486 | | | | | | 3,386,807 | | |
Post-Reverse Stock Split 1:11 | | | | | 9,090,909 | | | | | | 4,969,734 | | | | | | 1,042,260 | | | | | | 3,078,915 | | |
Post-Reverse Stock Split 1:12 | | | | | 8,333,333 | | | | | | 4,555,589 | | | | | | 955,405 | | | | | | 2,822,339 | | |
By: | |
By: | |